15 January 2019 - The Association of the British Pharmaceutical Industry has responded to the outcome of the meaningful vote on the Withdrawal Agreement and Political Deceleration.

Mike Thompson, chief executive of the ABPI, said:

“The focus of pharmaceutical companies is on making sure that medicines and vaccines get to patients whatever the Brexit outcome. This includes stockpiling and duplicating manufacturing processes here and in Europe. We continue to work as closely as possible with Government on no deal planning.

“But we reiterate that ‘no deal’ would prove to be extremely challenging. With time running out we hope Parliament will come together and quickly find a solution to the stalemate and reassure patients that medicines will not be disrupted come March 2019.”

Read ABPI press release